MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced participation in the virtual H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO Robert Barrow will join a panel discussing The Future of Mental Healthcare at 2:30 p.m. ET. A webcast will be available on-demand starting at 7:00 a.m. ET on the same day. MindMed is a clinical-stage biotech focused on developing psychedelic therapies for mental health and addiction, with a diverse drug pipeline that includes psilocybin, LSD, and MDMA.

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.

Details on the panel discussion can be found below.

Topic: The Future of Mental Healthcare
Date: Monday, December 6, 2021
Time: 2:30 p.m. ET

A webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December 6, 2021 at 7:00 a.m. ET for those registered for the event.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Media Contact: mindmed@150bond.com
Investor Contact: bmackle@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-present-at-hc-wainwright-2nd-annual-psychedelics-conference-301434349.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

What is the date of MindMed's participation in the H.C. Wainwright Conference?

MindMed will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021.

What is the topic of the panel MindMed CEO Robert Barrow will join?

Robert Barrow will join a panel discussing 'The Future of Mental Healthcare'.

What time will the MindMed panel discussion take place?

The panel discussion will take place at 2:30 p.m. ET on December 6, 2021.

Will there be a webcast of the MindMed conference presentation?

Yes, a webcast of the company presentation will be available on-demand starting at 7:00 a.m. ET on December 6, 2021.

What is the primary focus of MindMed's drug development pipeline?

MindMed's pipeline focuses on developing psychedelic-inspired medicines and therapies to address mental illness and addiction.